Clinical Trials on Hypersensitivity, Immediate in Netherlands

Total 340 results

Novartis Pharmaceuticals

Completed

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (3)

Healthy Volunteers | Atopic Dermatitis | Netherton Syndrome

Netherlands, United States
GlaxoSmithKline

Completed

Study In Adults And Adolescents With Seasonal Allergic Rhinitis.

Rhinitis, Allergic, Seasonal

Netherlands, Estonia, Russian Federation, Sweden, Latvia, Lithuania
Centocor, Inc.
Centocor BV

Completed

A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

Asthma

United Kingdom, United States, Germany, France, Poland, Bulgaria, Belgium, Czech Republic, Hungary, Netherlands, Sweden
UMC Utrecht
Eli Lilly and Company; Sanofi; AbbVie; LEO Pharma; Academisch Ziekenhuis Groningen

Recruiting

BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients With Atopic Dermatitis (BioDay)

Atopic Dermatitis

Netherlands
AstraZeneca
Amgen

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma (HORIZON)

Asthma

United States, Poland, United Kingdom, Korea, Republic of, Spain, France, China, Canada, Netherlands, Argentina, Mexico, Brazil, Hungary, Japan, Philippines, South Africa, Colombia
Pharming Technologies B.V.

Completed

A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration (OPERA)

Hereditary Angioedema | Genetic Disorders

Netherlands, Romania
Pharming Technologies B.V.

Completed

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary Angioedema | Genetic Disorders | Angioneurotic Edema

Netherlands, Romania
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma (VENTURE)

Asthma

Belgium, Israel, United States, Mexico, Argentina, Brazil, Canada, Chile, Colombia, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, Ukraine
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of C1-Esteraseremmer-N

Hereditary Angioedema Type I | Angioneurotic Edema

Netherlands
AstraZeneca

Completed

Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)

Asthma

Hungary, South Africa, Germany, Brazil, India, Spain, Netherlands, Poland, Switzerland
LEO Pharma

Completed

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Atopic Dermatitis

United States, France, Netherlands
LEO Pharma

Active, not recruiting

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

Atopic Dermatitis

Spain, United Kingdom, Czechia, France, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

Asthma

Germany, Slovakia, Bulgaria, Canada, Poland, Korea, Republic of, Netherlands, Japan
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment

Dermatitis, Atopic

France, United Kingdom, Spain, Belgium, Portugal, Netherlands, Finland, Czech Republic, Germany, Hungary, Italy
GlaxoSmithKline

Completed

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Asthma

Canada, Bulgaria, Estonia, Spain, Netherlands, Germany, Australia, Austria, Belgium, Finland, Ireland, Latvia, Macedonia, The Former Yugoslav Republic of, New Zealand, United Kingdom
Hoffmann-La Roche

Completed

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

Asthma

United States, United Kingdom, Belgium, Canada, France, Germany, Bulgaria, Denmark, Hungary, Italy, Latvia, Netherlands, Portugal, Russian Federation, Spain
GlaxoSmithKline

Completed

Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.

Asthma

United States, Argentina, Poland, Russian Federation, Belgium, Canada, Chile, France, Germany, Korea, Republic of, Netherlands, Peru, Philippines, South Africa, Sweden, Thailand
GlaxoSmithKline

Completed

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Asthma

Russian Federation, Belgium, Poland, Spain, Denmark, Italy, Sweden, Netherlands, France, Lithuania, Latvia, Norway
Novartis Pharmaceuticals

Completed

Dose Finding Study for QAW039 in Asthma

Asthma

United States, Colombia, India, Romania, South Africa, Italy, Hungary, France, Bulgaria, Turkey, Greece, Guatemala, Japan, Argentina, Austria, Mexico, Netherlands, Peru, Poland, Russian Federation, United Kingdom, Canada
GlaxoSmithKline

Completed

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

Asthma

United States, Australia, Canada, France, Germany, Netherlands, Poland, Mexico, United Kingdom, Czech Republic
Astellas Pharma Inc

Completed

Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment

Dermatitis, Atopic

France, Germany, Spain, Belgium, Netherlands, Finland, Austria, United Kingdom, Italy, Czech Republic, Switzerland, Portugal, Denmark
GlaxoSmithKline

Completed

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Netherlands, Poland, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, United Kingdom, Czechia, Mexico, Italy
OM Pharma SA

Terminated

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Atopic Dermatitis

Germany, France, Poland, Netherlands
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (FLASH)

Asthma

United States, Argentina, Italy, Mexico, Germany, Hungary, Netherlands, Poland, Spain, Korea, Republic of, Bulgaria, Ukraine, Serbia, Turkey, Slovakia, United Kingdom, Chile, Australia, Croatia, Japan, Romania, South Africa, France, S...
Almirall, S.A.

Recruiting

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope)

Eczema | Atopic Dermatitis

Germany, Netherlands, United Kingdom
RAPT Therapeutics, Inc.

Completed

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

Atopic Dermatitis

United States, Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

South Africa, Belgium, Germany, Australia, Netherlands, Bulgaria, Austria, Romania
GlaxoSmithKline

Completed

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

Asthma

United States, Argentina, Korea, Republic of, Netherlands, Philippines, Chile
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema) (UPDATE)

Atopic Dermatitis | Atopic Dermatitis Eczema

Netherlands
AstraZeneca

Completed

Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)

Asthma

United Kingdom, Switzerland, Belgium, France, Italy, Spain, Netherlands
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Asthma

United States, India, Spain, Italy, Israel, Netherlands, Russian Federation, Lebanon, South Africa, Czechia, Greece, Serbia, Argentina, Mexico, Slovakia, Canada, Taiwan, Malaysia, Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Asthma

United States, Argentina, Belgium, Canada, France, Germany, Israel, Japan, Netherlands, South Africa
Sanofi
Regeneron Pharmaceuticals

Completed

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Asthma

Spain, Canada, Denmark, Belgium, Japan, Korea, Republic of, Mexico, United States, Israel, Brazil, Australia, France, Germany, United Kingdom, Argentina, Chile, Colombia, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation and more
HAL Allergy

Completed

PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis

Allergic Rhinitis | Allergic Rhinoconjunctivitis

Belgium, Germany, Austria, Netherlands, Spain
AstraZeneca
PHARMO Institute for Drug Outcome Research

Completed

Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists

Pneumonia | Gastroenteritis | Seizures | Failure to Thrive | Hospitalized Cases of Angioneurotic Oedema | Acute Interstitial Nephritis and Thrombocytopenia

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Asthma

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Calypso Biotech BV

Completed

Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis

Celiac Disease | Eosinophilic Esophagitis

Netherlands, Belgium, Finland, Germany, Norway
Escient Pharmaceuticals, Inc

Recruiting

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)

Chronic Inducible Urticaria

Spain, United States, Germany, Canada, Netherlands
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.

Asthma

United States, Argentina, Germany, Romania, Russian Federation, Ukraine, Chile, Sweden, Mexico, Netherlands, Poland
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (NIMBLE)

Asthma

United States, Australia, Austria, Canada, Finland, France, Germany, Ireland, Italy, Japan, Netherlands, Norway, Puerto Rico, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, Israel, Portugal
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
Intellia Therapeutics

Enrolling by invitation

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Hereditary Angioedema

France, New Zealand, United Kingdom, Netherlands
AstraZeneca

Completed

Local Phase 4 Pan-European SMART Study

Asthma

Italy, Sweden, France, Russian Federation, Spain, United Kingdom, Germany, Finland, Norway, Belgium, Netherlands, Greece, Ireland, Iceland
AstraZeneca

Completed

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. (ANDHI)

Asthma

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
GlaxoSmithKline

Completed

A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Netherlands, Poland, Russian Federation, Spain, Ukraine, Belgium, Chile, Korea, Republic of, Czechia, Italy, United Kingdom

Clinical Trials on Hypersensitivity, Immediate in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations